COMMUNIQUÉS West-GlobeNewswire

Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights
31/03/2026
Shareholders approve acquisition of Aptose by Hanmi Pharmaceutical in “Go Private” transaction TUS+VEN+AZA triplet frontline therapy continues to demonstrate favorable safety and high rates of efficacy and MRD-negative [...]
LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year
31/03/2026
BOCA RATON, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer [...]
Jushi Holdings Inc. Reports Fourth Quarter and Full Year 2025 Financial Results
31/03/2026
Revenue of $262.9 Million for Full Year 2025, Up 2% Year-Over-Year, Reflecting Contributions from New Store Openings Operational Turnaround Advanced in 2025 with Meaningful Improvements in Cultivation Performance and [...]
20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress
31/03/2026
Full Year 2025 Revenue of $2.0 Million, up 17% from 2024 Gross Profit Increased 68% in FY 2025 and Gross Margin Expanded 900 bps State-Funded Firefighter Cancer Screening Program Expected to Drive Significant Revenue [...]
NeuroSalt Claims Evaluated: What the Pink Salt Trick Research Says About Neuro Salt Supplementation for Nerve Health
31/03/2026
An informational overview of NeuroSalt ingredients, pink salt trick marketing claims, nerve pain supplement research context, pricing, refund policy, and what to know before buying Neuro Salt in 2026 Lakeland, FL, March [...]
Fagron increases share capital through exercise subscription rights
31/03/2026
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 31 March 2026 – 7PM CET Fagron increases share capital through exercise subscription rights Fagron announces that as a result of the exercise of [...]
Stage4Hope™ Commits $2.5 Million to Memorial Sloan Kettering Cancer Center to Accelerate Breakthrough Cancer Research
31/03/2026
Nonprofit founded by Stage IV lung cancer patient supports precision oncology research aimed at expanding treatment options for advanced cancers ATLANTA, March 31, 2026 (GLOBE NEWSWIRE) -- Stage4Hope™ , a nonprofit [...]
BioPorto Advances U.S. Adult Urine NGAL Program with FDA Pre-Submission Request After Positive EPACRA AKI Cut Off Analysis
31/03/2026
March 31, 2026 Announcement no. 6 BioPorto Advances U.S. Adult Urine NGAL Program with FDA Pre-Submission Request After Positive EPACRA AKI Cut Off Analysis COPENHAGEN, DENMARK, 31 March 2026 – BioPorto A/S (“BioPorto” [...]
UPDATE - Lumina Therapy Alliance Expands National Footprint with Addition of The Therapy Group of DC, Reaching Nearly 400 Clinicians Nationwide
31/03/2026
NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Lumina Therapy Alliance , a growing national network of premier, in-person mental health practices, today announced that The Therapy Group of DC has joined its alliance. With [...]
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
31/03/2026
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 31 March 2026 at 18:00 EEST Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]
Indiana Overdose Deaths Drop 18% But Deadly New Substances Threaten to Reverse Progress
31/03/2026
The "State of Addiction in Indiana" report highlights significant progress and emerging challenges in the state's battle against addiction. Indianapolis, INDIANA, March 31, 2026 (GLOBE NEWSWIRE) -- Indiana Rehabs has [...]
Jupiter Neurosciences to Present at Emerging Growth Conference on April 2
31/03/2026
JUPITER, FL, March 31, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL ™ , a patented resveratrol-based [...]
Serenity Medical Receives U.S. FDA HDE Approval of the River™ Stent - the First Venous Stent Approved for Severe, Refractory Idiopathic Intracranial Hypertension (IIH)
31/03/2026
Landmark regulatory milestone makes the River stent available for adults with severe IIH – a debilitating, historically undertreated condition – who have failed medical therapy Serenity Medical partners with Radical [...]
Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease
31/03/2026
– A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks before disease transmission – IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS [...]
Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting
31/03/2026
Encouraging Phase 2 HIT data and recent FDA feedback support continued advancement of CAD-1005 as Cadrenal’s near-term development priority; broader 12-LOX platform remains a longer-term opportunity PONTE VEDRA, Fla., [...]
QHSLab (OTCQB:USAQ) Reports Strong Fiscal 2025 Results with Revenue Growth, Expanding Margins, and Significant Balance Sheet Improvement
31/03/2026
Integrated Service Program Growth Drives Revenue Expansion and Margin Improvement Delivering Improved Profitability and Debt Reduction in Fiscal 2025 Operational Momentum and Balance Sheet Restructuring Position Company [...]
Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain
31/03/2026
First clinical trial conducted in human subjects to evaluate CT2000 for the treatment of both acute ocular pain and chronic ocular surface pain commonly associated with dry eye disease CT2000 is a lead pipeline asset of [...]
Solésence Reports Fourth Quarter and Full-Year 2025 Financial Results
31/03/2026
Full Year 2025 record revenue of $62.1 million ROMEOVILLE, Ill., March 31, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science [...]
Onconetix Appoints David White as Chief Executive Officer and Sammy Dorf as Member of the Board of Directors
31/03/2026
Experienced Leadership Team Positioned to Execute Pending Transformative Acquisition of Realbotix LLC and Drive Long-Term Shareholder Value CINCINNATI, Ohio, March 31, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: [...]

Pages